

10/29/07 20

=> d his

(FILE 'HOME' ENTERED AT 16:18:35 ON 18 APR 2005)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 16:18:47 ON 18 APR 2005

L1 159614 S TRANSGEN? (7A) (SWINE OR PIG OR HOG OR MICE OR MOUSE OR RAT)  
L2 510 S CLOTT? (W) FACTOR (W) IX  
L3 18998 S LACTOFERRIN  
L4 32 S L1 AND L2  
L5 0 S L4 AND L3  
L6 134 S L1 AND L3  
L7 20 DUP REM L4 (12 DUPLICATES REMOVED)  
L8 87 DUP REM L6 (47 DUPLICATES REMOVED)  
L9 290029 S TRANSGEN?  
L10 0 S L9 AND L2 AND L3  
L11 328 S MAMMARY(3A)GLAND(3A) (PROMOTER OR PROMOTOR)  
L12 4 S L8 AND L11

=> d au ti so pi ab 1-4 l12

L12 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
IN Cooper, Julian D.; Velander, William Hugold; O'Sickey, Tanya K.  
TI Production of human Factor IX without WAP gene rescue in transgenic  
mammals and its use in treatment of hemophilia B  
SO PCT Int. Appl., 69 pp.

CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	-----	-----	-----	-----
-------	-------	-------	-------	-------

PI WO 2002077161 A2 20021003 WO 2002-US7532 20020311  
WO 2002077161 A3 20030403

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,  
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,  
US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,  
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1379677 A2 20040114 EP 2002-733841 20020311

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2002008030 A 20040225 BR 2002-8030 20020311

US 2004133930 A1 20040708 US 2004-471492 20040212

AB A non-human transgenic mammal encoding human FIX protein without the  
benefit of the presence of a complete milk gene sequence for gene rescue,  
and a signal sequence, active in directing newly expressed Factor IX into  
the milk of the animal at levels in an unactivated form that is suitable  
for subsequent processing for therapeutic applications in treating  
Hemophilia B is provided. The transgenic mammals are preferably  
pigs, cows, sheep, goats and rabbits. The transgenic mammal  
secretes 200-5000 ug Factor IX per mL of whole milk and has 5-140%  
specific activity as compared to Factor IX from human plasma as determined by  
an activated partial thromboplastin clotting time assay. The application  
include milk derivs. for oral delivery and oral tolerization in the  
treatment of Hemophilia B.

L12 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

IN Cooper, Julian D.; Velander, William Hugold; Butler, Stephen P.

TI Promoters for transgenic human Factor VIII expression in mammary  
epithelial cells and secretion into milk for treatment of Hemophilia A

SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

-----

PI WO 2002072023 A2 20020919 WO 2002-US7530 20020311

WO 2002072023 A3 20040115

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1402049 A2 20040331 EP 2002-723412 20020311

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2002008029 A 20040727 BR 2002-8029 20020311

US 2004117862 A1 20040617 US 2004-471493 20040212

AB A non-human transgenic mammalian animal, as described above, contains promoters for variant human Factor VIII gene expression, and a signal sequence and secretion motif that is active in directing newly expressed Factor VIII into the milk of the animal. Furthermore, Factor VIII is modified to improve its stability in milk and for therapeutic applications in treating Hemophilia A. The **transgenic** mammals are preferably pigs, cows, sheep, goats and rabbits. The transgenic mammal preferably secretes 20-1000 µg of human factor VIII/mL milk and the specific activity is at least 50-500% less than the specific activity of factor VIII isolated from human plasma as determined by an activated partial thromboplastin clotting time coagulation assay. The applications include milk derivs. used for oral delivery and oral tolerization in the treatment of Hemophilia A.

L12 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

IN L'Huillier, Phillip John; Vilotte, Jean-luc

TI A modified **mammary gland-specific promoter** containing a STAT5 binding site

SO PCT Int. Appl., 50 pp.

CODEN: PIXXD2

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

-----

PI WO 2001000860 A2 20010104 WO 2000-NZ109 20000623

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AB This invention relates to an isolated DNA mol. including a mammary specific promoter which has been modified by the insertion of at least one complete STAT5 binding site, said modified promoter providing enhanced frequency of expression of a heterologous gene to which it may be operably linked. STAT5 binding sites appear to play a role in gene expression in the lactating mammary gland and including the elements in the promoter leads to increased levels of expression of genes under control of such a promoter. Mammary gland-specific expression constructs with a reporter gene under control of promoters containing the STAT5 site were constructed and introduced into **transgenic mice**. Tissue specificity

was not absolute as low levels of expression of the reporter were found in other tissues that were different from those found for the unmodified promoters. Promoters carrying the STAT5 element showed normal patterns of developmental regulation in gestating mice although timings and levels of expression were altered with up to a 10-fold increase in expression of the reporter gene over control animals.

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
 IN Prieto, Pedro Antonio; Smith, David Fletcher; Cummings, Richard Dale; Kopchik, John Joseph; Mukerji, Pradip; Moremen, Kelley Wilson; Pierce, James Michael  
 TI Manufacture and secretion into milk of oligosaccharides and glycoconjugates typical of human milk by mammary gland-specific expression of the human genes for oligosaccharide biosynthetic enzymes  
 SO PCT Int. Appl., 51 pp.  
 CODEN: PIXXD2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9524495	A1	19950914	WO 1995-US967	19950124
	W: AU, CA, FI, JP, MX, NL, NZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5750176	A	19980512	US 1994-208889	19940309
	CA 2184686	AA	19950914	CA 1995-2184686	19950124
	AU 9516901	A1	19950925	AU 1995-16901	19950124
	AU 697523	B2	19981008		
	EP 750673	A1	19970102	EP 1995-908663	19950124
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 09510094	T2	19971014	JP 1995-523443	19950124
AB	Methods for genetic engineering of the milk of a non-human mammal is characterized so that it contains heterologous components produced as the secondary gene products of a heterologous gene integrated into the genome of the transgenic non-human mammal are described. The heterologous gene encodes an enzyme such as a human enzyme selected from the group consisting of glycosyltransferases, phosphorylases, hydroxylases, peptidases and sulfotransferases. Especially useful in the practice of the invention are human glycosyltransferases. The desired heterologous components include oligosaccharides, glycoconjugates. The oligosaccharides and glycoconjugates may be isolated from the milk of the transgenic mammals and used in the preparation of pharmaceuticals, diagnostic kits, nutritional products and the like. The whole milk may also be used to formulate nutritional products that provide special advantages. The transgenic milk may also be used in the production of specialized enteral nutritional products. Methods for transforming oocytes and screening preimplantation embryos for the presence of the transforming DNA are described. The cloning and expression of a cDNA for a human fucosyltransferase in <b>transgenic mice</b> using the whey acidic protein gene <b>promoter</b> to direct <b>mammary gland</b> -specific expression in mice is demonstrated.				

=>

=> d his

(FILE 'HOME' ENTERED AT 16:18:35 ON 18 APR 2005)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 16:18:47 ON 18 APR 2005

L1 159614 S TRANSGEN? (7A) (SWINE OR PIG OR HOG OR MICE OR MOUSE OR RAT)  
L2 510 S CLOTT? (W) FACTOR(W) IX  
L3 18998 S LACTOFERRIN  
L4 32 S L1 AND L2  
L5 0 S L4 AND L3  
L6 134 S L1 AND L3  
L7 20 DUP REM L4 (12 DUPLICATES REMOVED)  
L8 87 DUP REM L6 (47 DUPLICATES REMOVED)  
L9 290029 S TRANSGEN?  
L10 0 S L9 AND L2 AND L3

=> d au ti so pi 1-20 17

L7 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN  
AU Lindsay, Myles; Gil, Geun-Cheol; Cadiz, Armando; Velander, William H.;  
Zhang, Chenming; Van Cott, Kevin E.

TI Purification of recombinant DNA-derived factor IX produced in  
**transgenic pig** milk and fractionation of active and  
inactive subpopulations

SO Journal of Chromatography, A (2004), 1026(1-2), 149-157  
CODEN: JCRAEY; ISSN: 0021-9673

L7 ANSWER 2 OF 20 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN  
AU Xiao Yan-Ping [Reprint author]; Xi Ying [Reprint author]; Huang Wen-ying  
[Reprint author]; Huang Ying [Reprint author]

TI Detection of the integration of human F IX (hF IX) on chromosomes of  
**transgenic mice** by fluorescence *in situ* hybridization.

SO Yichuan, (May, 2002) Vol. 24, No. 3, pp. 232-236. print.  
ISSN: 0253-9772.

L7 ANSWER 3 OF 20 MEDLINE on STN DUPLICATE 1  
AU Huang Zan; Yan Jing-Bin; Huang Ying; Sun Qiong; Xiao Yan-Ping; Huang Ying;  
Zeng Yi-Tao  
TI High expression of human FIX(hFIX) in **transgenic mice**  
directed by goat beta-casein gene promoter.  
SO Yi chuan xue bao = Acta genetica Sinica, (2002) 29 (3) 206-11.  
Journal code: 7900784. ISSN: 0379-4172.

L7 ANSWER 4 OF 20 MEDLINE on STN  
AU Schneider Holm, Muhle Christiane; Douar Anne Marie; Waddington Simon;  
Jiang Qiu-Jie; von der Mark Klaus; Coutelle Charles; Rascher Wolfgang  
TI Sustained delivery of therapeutic concentrations of human **clotting**  
**factor IX**--a comparison of adenoviral and AAV vectors  
administered *in utero*.  
SO journal of gene medicine, (2002 Jan-Feb) 4 (1) 46-53.  
Journal code: 9815764. ISSN: 1099-498X.

L7 ANSWER 5 OF 20 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN  
AU Kaufhold, Antje [Reprint author]; Pleimes, Marc [Reprint author]; Herzog,  
Roland W. [Reprint author]; Fakharzadeh, Steven S.; Arruda, Valder R.  
[Reprint author]; Armstrong, Elina [Reprint author]; Margaritis, Paris  
[Reprint author]; High, Katherine A. [Reprint author]

TI Human factor IX expression in skin in a **transgenic mouse**  
model and indication for an advantage in using the collagen IV binding  
lacking factor IX mutant K5A.

SO Blood, (November 16, 2000) Vol. 96, No. 11 Part 1, pp. 213a. print.

Meeting Info.: 42nd Annual Meeting of the American Society of Hematology.  
San Francisco, California, USA. December 01-05, 2000. American Society of  
Hematology.  
CODEN: BLOOAW. ISSN: 0006-4971.

L7 ANSWER 6 OF 20 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on  
STN

AU Bevan S; Martin R (Reprint); McKay I A

TI The production and applications of genetically modified skin cells

SO BIOTECHNOLOGY & GENETIC ENGINEERING REVIEWS, (AUG 1999) Vol. 16, pp.  
231-256.

Publisher: INTERCEPT LTD, PO BOX 716, ANDOVER SP10 1YG, HANTS, ENGLAND.  
ISSN: 0264-8725.

L7 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2

AU Huang, Ying; Zhang, Kezhong; Huang, Wenyi; Lu, Daru; Huang, Ying; Ma,  
Zhanlu; Ren, Zhaorui; Qiu, Xinfang; Xue, Jinglun; Zeng, Yitao; Huang,  
Shuzhen

TI Expression of biologically active human **clotting factor**  
**IX** (hF IX) in the mammary gland of **transgenic**  
**mice**

SO Chinese Science Bulletin (1998), 43(15), 1294-1298

CODEN: CSBUEF; ISSN: 1001-6538

L7 ANSWER 8 OF 20 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on  
STN

AU Zhang K Z (Reprint); Jiang P H; Lu D R; Huang W D; Chen L; Xue J L; Qiu X  
F

TI Expression and regulation of hFIX minigene and cDNA driven by beta-casein  
gene in mouse mammary gland

SO SCIENCE IN CHINA SERIES C-LIFE SCIENCES, (AUG 1998) Vol. 41, No. 4, pp.  
406-412.

Publisher: SCIENCE CHINA PRESS, 16 DONGHUANGCHENGEN NORTH ST, BEIJING  
100717, PEOPLES R CHINA.

ISSN: 1006-9305.

L7 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN

AU Qiu, Xinfang; Zhang, Kezhong; Lu, Daru; Xue, Jinglun

TI mammary gland bioreactor for human **clotting factor**  
**IX**

SO Fudan Xuebao, Ziran Kexueban (1998), 37(4), 365-371

CODEN: FHPTAY; ISSN: 0427-7104

L7 ANSWER 10 OF 20 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on  
STN

AU YULL F; HAROLD G; WALLACE R; COWPER A; PERCY J; COTTINGHAM I; CLARK A J  
(Reprint)

TI FIXING HUMAN FACTOR-IX (FIX) - CORRECTION OF A CRYPTIC RNA SPLICING ENABLES  
THE PRODUCTION OF BIOLOGICALLY-ACTIVE FIX IN THE MAMMARY-GLAND OF  
**TRANSGENIC MICE**

SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF  
AMERICA, (21 NOV 1995) Vol. 92, No. 24, pp. 10899-10903.  
ISSN: 0027-8424.

L7 ANSWER 11 OF 20 MEDLINE on STN DUPLICATE 3

AU Boland E J; Liu Y C; Walter C A; Herbert D C; Weaker F J; Odom M W;  
Jagadeeswaran P

TI Age-specific regulation of **clotting factor** **IX**  
gene expression in normal and **transgenic mice**.

SO Blood, (1995 Sep 15) 86 (6) 2198-205.  
Journal code: 7603509. ISSN: 0006-4971.

L7 ANSWER 12 OF 20 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on

STN  
AU ALEXANDER M Y; BIDICHANDANI S I; COUSINS F M; ROBINSON C J M; DUFFIE E;  
AKHURST R J (Reprint)  
TI CIRCULATING HUMAN FACTOR-IX PRODUCED IN KERATIN PROMOTER  
**TRANSGENIC MICE** - A FEASIBILITY STUDY FOR GENE-THERAPY  
OF HEMOPHILIA-B  
SO HUMAN MOLECULAR GENETICS, (JUN 1995) Vol. 4, No. 6, pp. 993-999.  
ISSN: 0964-6906.

L7 ANSWER 13 OF 20 MEDLINE on STN DUPLICATE 4  
AU Hu Y; Qiu X; Xue J; Liu Z  
TI Regulation of human **clotting factor IX** cDNA  
expression in **transgenic mice**.  
SO Science in China. Series B, Chemistry, life sciences & earth sciences,  
(1995 Jul) 38 (7) 825-33.  
Journal code: 8913082. ISSN: 1001-652X.

L7 ANSWER 14 OF 20 MEDLINE on STN DUPLICATE 5  
AU Baru M; Axelrod J H; Nur I  
TI Liposome-encapsulated DNA-mediated gene transfer and synthesis of human  
factor IX in mice.  
SO Gene, (1995 Aug 19) 161 (2) 143-50.  
Journal code: 7706761. ISSN: 0378-1119.

L7 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 6  
AU Hu, Yi-Ping; Qiu, Xin-Fang; Xue, Jing-Lun  
TI Polymerase chain reaction (PCR) in detection of **transgenic**  
**mice** harboring human **clotting factor**  
**IX** cDNA  
SO Chinese Science Bulletin (1994), 39(13), 1133-8  
CODEN: CSBUEF; ISSN: 1001-6538

L7 ANSWER 16 OF 20 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on  
STN  
AU WILMUT I (Reprint); ARCHIBALD A L; MCCLENAGHAN M; SIMONS J P; WHITELAW C B  
A; CLARK A J  
TI PRODUCTION OF PHARMACEUTICAL PROTEINS IN MILK  
SO EXPERIENTIA, (1991) Vol. 47, No. 9, pp. 905-912.

L7 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN  
IN Archibald, Alan Langskill; Clark, Anthony John; Harris, Stephen;  
McClenaghan, Margaret; Simons, John Paul; Whitelaw, Christopher Bruce Ale  
TI Manufacture of protein with transgenic mammals  
SO PCT Int. Appl., 101 pp.  
CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9005188	A1	19900517	WO 1989-GB1343	19891113
W: AU, DK, FI, HU, JP, KR, NO, SU, US RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AU 8944943	A1	19900528	AU 1989-44943	19891113
AU 628101	B2	19920910		
EP 396699	A1	19901114	EP 1989-912273	19891113
EP 396699	B1	19971001		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 03505674	T2	19911212	JP 1989-511400	19891113
JP 3141999	B2	20010307		
AT 158817	E	19971015	AT 1989-912273	19891113
US 5861299	A	19990119	US 1994-343884	19941117
US 5650503	A	19970722	US 1994-359854	19941220
US 6548735	B1	20030415	US 1997-781518	19970109

L7 ANSWER 18 OF 20 MEDLINE on STN

AU Wilmut I; Archibald A L; Harris S; McClenaghan M; Simons J P; Whitelaw C B; Clark A J  
TI Modification of milk composition.  
SO Journal of reproduction and fertility. Supplement, (1990) 41 135-46. Ref: 58  
Journal code: 0225652. ISSN: 0449-3087.

L7 ANSWER 19 OF 20 MEDLINE on STN DUPLICATE 7  
AU Choo K H; Raphael K; McAdam W; Peterson M G  
TI Expression of active human blood **clotting factor IX** in **transgenic mice**: use of a cDNA with complete mRNA sequence.  
SO Nucleic acids research, (1987 Feb 11) 15 (3) 871-84.  
Journal code: 0411011. ISSN: 0305-1048.

L7 ANSWER 20 OF 20 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN  
AU CHOO K H [Reprint author]; RAPHAEL K; MCADAM W; PETERSON M G  
TI EXPRESSION OF ACTIVE HUMAN BLOOD **CLOTTING FACTOR-IX IN TRANSGENIC MICE**.  
SO American Journal of Human Genetics, (1986) Vol. 39, No. 3 SUPPL, pp. A192.  
Meeting Info.: 37TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HUMAN GENETICS, PHILADELPHIA, PA., USA, NOV. 2-5, 1986. AM J HUM GENET.  
CODEN: AJHGAG. ISSN: 0002-9297.

12/18/2001, 7:20

## Freeform Search

---

<b>Database:</b>	US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database EPO Abstracts Database JPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins
<b>Term:</b>	12 and 13 and L6
<b>Display:</b>	20 Documents in <u>Display Format:</u> [ ] Starting with Number [1]
<b>Generate:</b>	<input type="radio"/> Hit List <input checked="" type="radio"/> Hit Count <input type="radio"/> Side by Side <input type="radio"/> Image

---

**Search** **Clear** **Interrupt**

---

### Search History

---

**DATE:** Monday, April 18, 2005 [Printable Copy](#) [Create Case](#)

**Set Name** **Query**  
side by side

**Hit Count** **Set Name**  
result set

*DB=PGPB,USPT; PLUR=YES; OP=AND*

<u>L7</u>	l2 and l3 and L6	8	<u>L7</u>
<u>L6</u>	transgen\$ near7 (swine or pig or hog)	2049	<u>L6</u>
<u>L5</u>	l1 and L4	14	<u>L5</u>
<u>L4</u>	l2 with l3	16	<u>L4</u>
<u>L3</u>	lactoferrin	2119	<u>L3</u>
<u>L2</u>	clott\$ adj factor adj IX	210	<u>L2</u>
<u>L1</u>	transgen\$	39287	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)

## Search Results - Record(s) 1 through 8 of 8 returned.

1. [20040133932](#). 12 Feb 04. 08 Jul 04. Transgenic proteins from multi-gene systems, methods, compositions, uses and the like relating thereto. Cooper, Julian D., et al. 800/8; A01K067/00.

2. [20040133930](#). 12 Feb 04. 08 Jul 04. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses. Cooper, Julian D., et al. 800/7; 800/15 A01K067/027.

3. [20040117862](#). 12 Feb 04. 17 Jun 04. Production of high levels of transgenic factor VII with engineered stability and its therapeutic uses. Cooper, Julian D., et al. 800/7; 800/14 A01K067/027.

4. [6545199](#). 28 Jul 00; 08 Apr 03. Embryonic germ cells, method for making same, and using the cells to produce a chimeric porcine. Anderson; Gary B., et al. 800/21; 435/325 435/455 800/17. C12N015/09 C12N015/63 C12N015/00 C12N005/00.

5. [6194635](#). 20 Sep 96; 27 Feb 01. Embryonic germ cells, method for making same, and using the cells to produce a chimeric porcine. Anderson; Gary B., et al. 800/21; 435/325 435/455 800/17. C12N015/09 C12N015/63 C12N015/00 C12N005/00.

6. [5942435](#). 06 Jun 95; 24 Aug 99. Transgenic swine compositions and methods. Wheeler; Matthew B.. 435/325; 435/378 800/24. C12N005/00 C12N015/00.

7. [5907080](#). 30 Nov 95; 25 May 99. Method for development of transgenic dwarf goats. Karatzas; Costas, et al. 800/25; 435/455 800/14 800/21 800/22 800/23 800/7. C12N015/00 C12N015/09 C12N015/63 C12N005/00.

8. [5523226](#). 14 May 93; 04 Jun 96. Transgenic swine compositions and methods. Wheeler; Matthew B.. 435/325; 424/9.1 435/378 435/7.23. C12N005/00.

[Generate Collection](#)[Print](#)

Terms	Documents
L2 and L3 and L6	8

[Prev Page](#)   [Next Page](#)   [Go to Doc#](#)